Welcome to our dedicated page for Prime Medicine news (Ticker: PRME), a resource for investors and traders seeking the latest updates and insights on Prime Medicine stock.
Prime Medicine, Inc. (Nasdaq: PRME) is a biotechnology company that describes itself as committed to delivering a new class of differentiated one-time curative genetic therapies using its proprietary Prime Editing platform. The PRME news feed on Stock Titan aggregates company press releases and other coverage so readers can follow how this Prime Editing strategy progresses from research to clinical data and corporate milestones.
According to its public announcements, Prime Medicine is advancing a diversified portfolio of investigational programs focused on liver, lung, and immunology and oncology. News items highlight specific programs such as PM577 for H1069Q-driven Wilson’s Disease, PM647 for Alpha-1 Antitrypsin Deficiency, an in vivo Cystic Fibrosis program supported by the Cystic Fibrosis Foundation, and PM359 for p47phox chronic granulomatous disease. Updates may include preclinical data presentations, first-in-human clinical data, and information about how Prime Editing is being applied across these indications.
Investors and observers can also use the PRME news page to follow corporate developments disclosed by the company, such as participation in healthcare and genetic medicines conferences, leadership appointments, financing transactions, and strategic collaborations, including efforts with Bristol Myers Squibb on Prime Edited CAR-T products. Because Prime Medicine regularly issues press releases in connection with quarterly financial results, pipeline updates, and investor events, the news stream offers a way to track changes in its pipeline priorities, regulatory plans, and capital markets activity over time.
By reviewing the PRME news feed, users can see how Prime Medicine communicates progress on its Prime Editing platform, key disease programs, and business strategy. Bookmarking this page provides a single location to review recent announcements, clinical and preclinical data disclosures, and other material updates that the company has chosen to release publicly.
Summary not available.
Summary not available.
Summary not available.
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology firm focused on innovative one-time curative genetic therapies, announced that its CEO, Keith Gottesdiener, will present a corporate overview at the Guggenheim Healthcare Talks on April 3, 2023, at 3:55 p.m. ET in New York, NY. A live audio webcast will be accessible in the company’s News & Events section at www.primemedicine.com, with a replay available for 30 days post-event. Prime Medicine uses advanced Prime Editing technology aimed at treating a wide range of diseases by precisely correcting genetic mutations.
Prime Medicine, a biotechnology firm, reports significant progress in the fourth quarter and full year of 2022. Key highlights include:
- Successful upsized IPO raising $199 million.
- Nominated PM359 as the first development candidate for treating Chronic Granulomatous Disease (CGD).
- New preclinical data showing effective genetic editing and minimal off-target activity.
- Research & Development expenses totaled $86.7 million for 2022, with a net loss of $121.8 million.
- Cash position improved to $293.9 million as of December 31, 2022.
Prime Medicine anticipates moving forward with IND-enabling studies in 2023 and further development of its Prime Editing platform.
Prime Medicine, a leading biotechnology company listed on Nasdaq under the symbol PRME, announced that Dr. Keith Gottesdiener, President and CEO, will present a corporate overview at the Cowen 43rd Annual Health Care Conference on March 6, 2023, at 9:50 a.m. ET in Boston, MA. This presentation will highlight the company's innovative approach to one-time curative genetic therapies utilizing Prime Editing technology, which can potentially address around 90 percent of disease-causing genetic mutations. A live audio webcast will be available on their website, with a replay accessible for 30 days following the event.
Prime Medicine, Inc. (Nasdaq: PRME) announced significant advancements in its Prime Editing technology, focusing on preclinical proof-of-concept for treating diseases like Friedrich’s ataxia and cystic fibrosis. Preliminary safety analyses show no off-target activity in Wilson’s disease cells, reinforcing the platform's specificity. The company also reported progress in integrating kilobase-sized DNA into human T cells and efficient delivery methods for various tissues in rodents. With a strong cash position expected to fund operations into 2025, multiple catalysts are anticipated throughout 2023.
Prime Medicine, Inc. (Nasdaq: PRME) announced that CEO Keith Gottesdiener will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 8:15 a.m. PT in San Francisco, CA. The event will be available via live audio webcast on the company's website, with a replay accessible for 30 days post-presentation. Prime Medicine focuses on innovative genetic therapies using Prime Editing technology, which aims to address a wide range of diseases by potentially repairing 90% of known genetic mutations.
Prime Medicine, Inc. (Nasdaq: PRME) has successfully completed its upsized initial public offering, issuing 10,294,118 shares at $17.00 each, raising approximately $175 million before expenses. The underwriters also hold a 30-day option to purchase an additional 1,544,117 shares. Shares started trading on Nasdaq on October 20, 2022. This offering aims to fund the development of Prime Editing technology, which has the potential to address a wide range of genetic diseases by correcting mutations.
Prime Medicine, Inc. (Nasdaq: PRME) has priced its upsized initial public offering of 10,294,118 shares at $17.00 each, aiming to raise approximately $175 million before expenses. The offering, managed by J.P. Morgan, Goldman Sachs, Morgan Stanley, and Jefferies, will commence trading on the Nasdaq Global Market on October 20, 2022, and is set to close on October 24, 2022. The company focuses on innovative genetic therapies using Prime Editing technology, which targets a wide range of genetic diseases.